From the Report:
"The company completed a randomised clinical study on its Permetrex product, in collaboration with Germany’s BioSkin GmbH and Professor Jim Krueger of Rockefeller University in New York, to establish the mechanism of action of its CBD product in skin disease. Results showed that the product has significantanti-inflammatory and immune-modulating activity."
... that refers to the BTX half-full yet overflowing trial.
Mechanism is said to put a shine on patent applications - maybe akin to tightening the cylinder-head bolts to the correct tension in the correct order.
Antimicrobial platform - BTX 1801 Phase 2a clinical study, page-70
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.015(3.90%) |
Mkt cap ! $672.4M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $2.603M | 7.036M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 292539 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 24998 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |